Lilly Forward-Looking Statement This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about the potential of olaratumab as a treatment of advanced soft tissue sarcoma and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There can be no guarantee that future study results and patient experience will be consistent with the study findings to date. There can also be no guarantee that olaratumab will receive regulatory approval for any future indications or that it will prove to be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, please see the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements.
Refer to: Karen Glowacki; kglowacki@lilly.com; 317-370-1177 (media)Philip L. Johnson; philip_johnson_l@lilly.com; 317-655-6874 (investors)
Logo -- http://photos.prnewswire.com/prnh/200312... [http://photos.prnewswire.com/prnh/200312...]
Andalucía
